, M.D.,
Bernard Halpern, XX.X.XXXXXXXXX XXXXXXX, B.S.
Abstract
XXX reason XXX XXX increased XXXXXXXXX XXX XXXXXXXX of XXXXXXXXXX in XXXXXXXX XXXXXXXX has never been XXXXXXXXXXXXXX explained. This investigation XXX designed XX study XXX circulating antibody XXXXXXXX in alloxan XXXXXXXX, insulin XXXXXXX XXXXXXXX XXX XXXXXX XX-X XXXX XXXXXXXX XXXX XXXXXX XXXXX XXXXXXX. XXXX those animals treated XXXX alloxan XXX XXX elevated XXXXX XXXXXXX XXXXXX (XXX mg./XXX ml. or XXXXXX) were included in XXX study, together with a XXXXX of normal XXXXXXX. Animals were XXXX from XXX XXXXXXX sinus and XXX serum analyzed XXX XXXXXXX XXXXXXX capacity of BSA, XXXXXXX concentration XXX serum proteins. XXX was XXXXXXXXX with I-131 and the antigen binding capacity of each serum XXXXXX XXX XXXXXXXXXX XX micrograms of BSA XXXXXXXX bound by X ml. XX undiluted serum. XXX XXXXXXX XXXXXXXXXXX that XXXXX XX XX significant difference in XXXXXXXX XXXXXXXX XX XXXXXXX XXXXXXX mice, XXXXXXX treated XXXX given insulin XXX normal XXXX XXXX immunized XXXX XXX under the conditions of the experiments. XX XXX XXXXXXX treated XXXXX XXX be considered a laboratory XXXXX of XXXXXXXX mellitus in man, XXX results XXXXXXXXX herein would be consistent with those studies of diabetics which have shown XX primary XXXXXX in XXXXX XXXXXX systems.
XXXXXXXXX &XXXX; 1971 XX the XXXXXXXX XXXXXXXX XXXXXXXXXXX">